Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 16 Results

Title
Intervention Indication Therapeutic Area Year Actions
Cabozantinib with nivolumab and ipilimumab for previously untreated advanced or metastatic renal cell carcinoma Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Renal cell carcinoma (RCC) Renal Cancer 2023 View  |  Download
Cemiplimab in combination with chemotherapy for advanced or metastatic non-small cell lung cancer – first-line Cemiplimab (Libtayo; REGN2810) , Ipilimumab (Yervoy; BMS 734016; MDX 101) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H) Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Colon cancer Gastrointestinal Cancer 2017 View  |  Download
Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Head and neck cancer Head and Neck Cancer 2017 View  |  Download
Nivolumab in combination with ipilimumab for cisplatin-ineligible patients with untreated, unresectable or metastatic urothelial cancer– first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Bladder cancer Oncology , Urological Cancer 2021 View  |  Download
Nivolumab in combination with ipilimumab for early stage non-small cell lung cancer -neoadjuvant Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Nivolumab in combination with ipilimumab for gastric or gastroesophageal junction cancer – first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Gastric cancer Gastrointestinal Cancer 2021 View  |  Download
Nivolumab in combination with ipilimumab for malignant pleural mesothelioma – first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Malignant pleural mesothelioma (MPM) Lung and Respiratory Cancer 2019 View  |  Download
Nivolumab in combination with ipilimumab for oesophageal squamous cell carcinoma – first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Oesophageal cancer Head and Neck Cancer 2019 View  |  Download
Nivolumab in combination with ipilimumab for previously untreated unresectable or metastatic urothelial cancer – first-line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Urothelial cancer Urological Cancer 2020 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications